Next Phase Newsletter

A New York based venture investment firm with a single LP looks to make growth-stage investments in the form of preferred equity, ranging from $1M-$5M initially, with additional capital reserved for follow-on financings, typically up to $10M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 2-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.

The firm makes about one-half of its investments in healthcare, and is open to any healthcare companies that do not require FDA approval for their product/service. However, the firm focuses on B2B-oriented healthcare services and healthcare IT solutions.

The firm typically looks for growing companies with a run rate of $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and will work with first-time entrepreneurs. The firm looks to take a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate VC firm that invests strategically on behalf of a biopharmaceutical company invests in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is open to opportunities worldwide.

The firm invests in three indication areas: oncology, immunology, and hematology. The fund is interested in therapeutic, medical device and healthcare IT opportunities in these three areas, but does not invest in diagnostics. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).

The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based venture capital firm established in 2014 invests in a variety of sectors including healthcare services, biotech, and medical devices. The firm typically invests $50K-$500K per company and prefers to lead investments. The firm is seeking 1-2 new investments within the next year and is open to companies based in the U.S.

The firm is open to all sectors of life science technology, though has a particular interest in healthcare services and software; therapeutics and drug discovery; and diagnostics and devices. The firm typically looks at proof-of-concept technology, and is open to preclinical technology close to receiving IND and entering clinical trials. The firm is indication agnostic.

The firm typically seeks companies that have under $5M pre-money valuations, and takes a board seat after an investment.     

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A NASDAQ-listed company which acquires, develops and commercializes promising drugs and technologies is seeking asset partnerships. The firm provides partners with committed investment capital, experienced start-up management, world-class scientific expertise, and shared facilities. The firm does not make typical equity investments, but rather is open to a variety of deal structures to acquire or co-develop assets, including traditional milestone-based licensing deals, joint ventures, option agreements and equity arrangements (no less than 50% equity stake).

The company focuses primarily on therapeutic opportunities, but will consider diagnostic and medical devices that are based on compelling science. Current areas of interest include dermatology, rare diseases, oncology, acute care, and specialist products (eg. in hepatology, GI, women’s health).

The firm has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A sector-exclusive life sciences venture and growth equity fund based in Shanghai, China, manages 5 funds with AUM of USD 500M. The firm currently investing from a fund that closed in April 2015, backed by a pharma firm as well as a number of world-class institutional investors. The firm is stage agnostic, investing in early, growth, and up to pre-IPO opportunities. The firm’s team of investment professionals all have a healthcare background. Investment size is USD 5-45 million per company. The firm prefers to lead or co-lead a financing round, and typically requires a board seat. With both USD and RMB funds, the firm on China but also considers opportunities from US, Canada, and Europe.

The firm focuses 75% on therapeutics, with an emphasis on oncology, cell therapy, and biologics. Small molecules are less of interest. The firm is also interested in medical devices, diagnostics, animal health. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large global pharmaceutical company seeks to make strategic investments into early-stage companies that are aligned with the parent firm’s R&D focus. For equity investments, the firm prefers to maintain <15% equity stake in the company, and participate in rounds where lead investors include VC firms or other institutional investors. The venture arm is able to contribute additional non-dilutive resources that can increase the probability of successful product and business development. The group maintains a flexible approach to all investment opportunities. The group seeks to make investments of up to $5M, and usually targets 3-4 investments per year.

The firm’s core focus is on therapeutics, but is also open to invest in improved efficiencies in drug discovery & development, new platforms for target and drug discovery, drug delivery and is beginning to look into digital health solutions that fall within the company’s main R&D focus areas. Currently, the firm is most interested in chronic inflammatory and immune disorders (particularly for gastrointestinal diseases), oncology, regenerative medicine and vaccines; not currently as interested in cardiovascular or CNS indications. The firm does not invest in traditional medical devices or diagnostics. Although the firm is just beginning to explore digital health/health IT, the firm would be open to evaluating healthcare-related software platforms, wearable for health monitoring or digital, companion diagnostics (digital solutions that complement traditional therapeutics).

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm is open to follow-on rounds of investment where they assist in driving promising projects to fruition, and strategic alignment of the investment remains true. The firm respects the autonomy of the institutions it invests in, and will usually seek passive investment terms, providing strategic management input only when requested. However, the firm will require board observer rights and will usually request scientific review rights when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital fund founded in 1992 and based in the US Mid-Atlantic region focuses on healthcare IT and diagnostics. The firm primarily invests in the growth stage at the series A or B round, though if investing early, the firm would be part of a syndicate. The firm typically invests around $1M-$15M into early companies, and $10M-$30M into growth stage companies. The firm seeks to make 10-15 new investments within the next year. The firm focuses on companies based in USA and Canada due to practical matters, though may be open to investments on a global level.

The firm has a primary focus in healthcare IT, particularly in EMR companies, analytics, and any next generation IT tools for enterprise or ambulatory settings. The firm’s secondary focus is in tools and diagnostics, specifically in 510K genomics diagnostics, though is open to any kind of new diagnostic tool or test. The firm currently does not have interest in therapeutics or medical technology. The firm prefers companies with a commercialized product that is producing revenue, though does not have a revenue requirement and may be open to clinical stage products.

The firm primarily invests in growth stage companies where 80% of their invested companies have revenue with a product looking to expand in the market and 20% of invested companies at the pre-revenue, close to commercialization stage. The firm typically invests in pre-revenue companies when the technology is close to commercialization (i.e. steps away from approval) and/or when the company has a strong management team with members the firm has known from before. The firm does not have a management team requirement and will take a board seat depending on the size and ownership of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com